Polyethylene Glycol (PEG)-Biotin

GWB-36AB1D

KLH-PEG with terminal methoxy group was used as an immunogen. This antibody recognizes the terminal methoxy group of the PEG molecule. Anti-PEG-47-Biotin is prepared by the biotinylation of the antibody via primary amines.

WB: 15. 6 ng/mLIHC: 1:100. Polyethylene glycol(PEG)is a family of long chain polymers attached to a glycerine backbone. It is a nonionic nontoxic biocompatible strongly hydrophilic polymer which has a large exclusion volume in aqueous solution (1). The covalent attachment of PEG is now commonly used to modify a variety of proteins and drugs (2 3). The modification of a biopharmaceutical with polyethylene glycol (PEG) increases its hydrodynamic radius reduces immunogenicity and proteolytic cleavage. Other benefits include decelerated renal excretion improved stability towards proteolysis and increased solubility of the biopharmaceutical in aqueous solutions (4). As examples PEG-adenosine deaminase (Adagen) is used for the treatment of severe combined immunodeficiency syndrome PEG-asparaginase (Oncaspar) is used for the treatment acute lymphoblastic leukemia PEG-interferon 2a (Pegasys) is used for the treatment Hepatitis C Branched PEG-anti-VEGF aptamer (Pegaptanib Macugen) is used for the treatment Macular degeneration(age-related) (5). An Anti-PEG antibody can be used to monitor a drug\' s pharmacokinetics including distribution metabolism and excretion. In addition it can be used for the quality control of pegylated molecules in ELISA WB and flow cytometery. 1. Guiotto A. et al. (2004) Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg. Med. Chem. 12 50312. Wong S. S. (1991) Reactive groups of proteins and their modifying agents. In Chemistry of protein conjugation and cross-linking p. 13 CRC Press3. Caliceti P. et al. (1993) Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification. J. Bioact. Comp. Polym. 8 414. Frank Leenders celares GmbH Berlin Germany. (2006) PEGylation technology and biopharmaceuticals. Biopharmaceuticals. 6 39-405. Francesco M. Veronese Gianfranco Pasut. (2005) PEGylation successful approach6. Manufactured under U. S. Patents No. 5 675 063 and 7 429 487